

DAFTAR PUSTAKA

1. McNeil C. Annual cancer statistics report raises key questions. *J Natl Cancer Inst.* 2006;98(22):1598–9.
2. SEER. Cancer Stat Facts: Thyroid Cancer. National cancer institute. National Cancer Institute; 2018.
3. Pasaribu ET. Epidemiologi dan Gambaran Klinis Kanker Tiroid. 2006;39(3):1–4.
4. Kweon SS, Shin MH, Chung IJ, Kim YJ, Choi JS. Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, south korea. *Jpn J Clin Oncol.* 2013;43(10):1039–46.
5. Adham M, Aldino N. Diagnosis Dan Tatalaksana Karsinoma Tiroid Berdiferensiasi. Vol. 48, *Oto Rhino Laryngologica Indonesiana*. Jakarta: Departemen Telinga Hidung Tenggorok - Bedah Kepala Leher Fakultas Kedokteran Universitas Indonesia; 2019. hal. 197.
6. Diagnosis of Cancer Thyroid [Internet]. National Cancer Institute; 2012. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415174/>
7. National Comprehensive Cancer Network. Thyroid cancer [Internet]. Vol. 25, *Cancer Investigation.* 2022. Tersedia pada: <https://jncn.org/view/journals/jncn/20/8/article-p925.xml>
8. Perrier ND, Brierley JD, Tuttle RM. Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2018;68(1):55–63.
9. Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z. Thyroglobulin as a tumor marker in differentiated thyroid cancer – Clinical considerations. *Acta Clin Croat.* 2018;57(3):518–27.
10. Oktahermoniza O, Harahap WA, Tofriza T, Rasyid R. Analisis Ketahanan Hidup Lima Tahun Kanker Tiroid yang Dikelola di RSUP Dr. M. Djamil Padang. *J Kesehat Andalas.* 2013;2(3):151.
11. Soeroso dkk J., Isbagio H., Kalim H., Broto R. PR. *Buku Ajar Ilmu Penyakit Dalam.* 4 ed. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2014. 2539–2549 hal.
12. Indrasena BSH. Use of thyroglobulin as a tumour marker. *World J Biol Chem.* 2017;8(1):81.
13. Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Clinical Study Serum Thyroglobulin : Preoperative Levels and Factors Affecting Postoperative Optimal Timing following Total Thyroidectomy. 2019;2019.
14. Djokomoeljanto. Tirotoksikosis. Dalam: *Buku Ajar Tiroidologi Klinik*. Semarang: Badan Penerbit Undip; 2007. 217–73 hal.
15. Sabiston DC. *Buku Ajar Ilmu Bedah Sabiston.* 2 ed. Vol. 13, *Nucl. Phys.* Jakarta; 1959. 104–116 hal.
16. Abrams DB, Turner JR, Baumann LC, Karel A, Collins SE, Witkiewitz K, et al. American Cancer Society. *Encycl Behav Med.* 2013;79–81.
17. Popoveniuc G, Jonklaas J. Thyroid Nodules. *Med Clin North Am* [Internet]. 2012;96(2):329–49. Tersedia pada: <http://dx.doi.org/10.1016/j.mcna.2012.02.002>
18. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for

- Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016;26(1):1–133.
19. Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi A. Malignancy in solitary thyroid nodule: A clinicoradiopathological evaluation. *Indian J Endocrinol Metab*. 2015;19(4):498–503.
 20. Zimmermann MB, Galetti V. Iodine intake as a risk factor for thyroid cancer: A comprehensive review of animal and human studies. *Thyroid Res [Internet]*. 2015;8(1):1–21. Tersedia pada: <http://dx.doi.org/10.1186/s13044-015-0020-8>
 21. Gérard AC, Humblet K, Wilvers C, Poncin S, Derradji H, De Ville De Goyet C, et al. Iodine-deficiency-induced long lasting angiogenic reaction in thyroid cancers occurs via a vascular endothelial growth factor-hypoxia inducible factor-1-dependent, but not a reactive oxygen species-dependent, pathway. *Thyroid*. 2012;22(7):699–708.
 22. Sun X, Shan Z, Teng W. Effects of increased iodine intake on thyroid disorders. *Endocrinol Metab*. 2014;29(3):240–7.
 23. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. *J Clin Endocrinol Metab*. 2009;94(5):1612–7.
 24. Wang F, Wang Y, Wang L, Wang X, Sun C, Xing M, et al. Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer. *Tumor Biol*. 2014;35(11):11375–9.
 25. Kumar V, Abbas AK, Aster JC. *Buku Ajar Patologi Robbins*. 7 ed. Vol. 5, Elsevier. Jakarta: Buku Kedokteran EGC; 2013. 923 hal.
 26. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group W. Thyroid cancer : ESMO Clinical Practice Guidelines for. 2012;23(Supplement 7).
 27. Silver CE. Surgical management of well differentiated thyroid carcinoma. *Bull New York Acad Med J Urban Heal*. Oktober 1986;62(8):854–61.
 28. Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. *Lancet Diabetes Endocrinol*. 2018;6(4):287–98.
 29. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, et al. American association of Clinical Endocrinologists, American college of endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update. *Endocr Pract*. 2016;22(May):1–60.
 30. Soeroso dkk J., Isbagio H., Kalim H., Broto R. PR. *Buku Ajar Ilmu Penyakit Dalam*. 6 ed. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2014. 2539–2549 hal.
 31. American Cancer Society. How to diagnosis cancer thyroid. 2016; Tersedia pada: <https://www.cancer.org/cancer/types/thyroid-cancer/detection-diagnosis-staging.html>
 32. Slamet Suyono. *Buku Ajar Ilmu Penyakit Dalam, Edisi III Jilid II*. VI. Jakarta; 2012. 975 hal.
 33. NationalComprehensiveCancerNetwork. NCCN Clinical Practice

- Guidelines in Oncology: Thyroid Carcinoma. NCCN Guidel [Internet]. 2022;1–134. Tersedia pada: <https://pubmed.ncbi.nlm.nih.gov/35948029/>
34. Reichenbach A, Bringmann A, Reader EE, Pournaras CJ, Rungger-Brändle E, Riva CE, et al. Peraturan Menteri Kesehatan Republik Indonesia nomor 25 tahun 2016. *Prog Retin Eye Res.* 2019;561(3):S2–3.
 35. Wisescistiati MV, Wetan NGAAMY, Manuaba IBTW, Adiputra PAT. Gambaran Pasien Karsinoma Tiroid Berdiferensiasi. 2022;11(4).
 36. Dewi, I Gusti Ayu m Prita PATA. Karakteristik Penderita Kanker Tiroid Di Bagian Bedah Onkologi Rsup Sanglah Denpasar Tahun 2009-2012. *J Fak Kedokt Univ Udayana.* 2015;2–9.
 37. Sadrina AN. Hubungan usia, jenis kelamin dan tempat tinggal terhadap jenis karsinoma tiroid di rsud ulin banjarmasin tahun 2018-2019. Banjarmasin; 2021.
 38. Rahbari R, Zhang L, Kebebew E. Rahbari et al-2010-Futur Oncol. 2010;1771–9.
 39. Cherlyna. Efektivitas Terapi Iodin Radioaktif Terhadap Papillary Thyroid Carcinoma Pascatiroidectomi: Dinamika Kadar Tiroglobulin dan Antibodi Tiroglobulin. Hassanuddin; 2020.

